AUB ScholarWorks

Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: A randomized controlled trial

Show simple item record

dc.contributor.author Fuleihan G.E.-H.
dc.contributor.author Salamoun M.
dc.contributor.author Mourad Y.A.
dc.contributor.author Chehal A.
dc.contributor.author Salem Z.
dc.contributor.author Mahfoud Z.
dc.contributor.author Shamseddine A.
dc.contributor.editor
dc.date Jun-2005
dc.date.accessioned 2017-10-05T15:38:17Z
dc.date.available 2017-10-05T15:38:17Z
dc.date.issued 2005
dc.identifier 10.1210/jc.2004-1444
dc.identifier.isbn
dc.identifier.issn
dc.identifier.uri http://hdl.handle.net/10938/16250
dc.description.abstract Purpose: Mortality from breast cancer has decreased in large part because of adjuvant chemotherapy. Sequelae of therapy include ovarian failure and bone loss, loss that would increase these patients' risk of fracture with aging. In this study, we assessed the efficacy of pamidronate in preventing such loss. Patients and Methods: The study was a 1-yr randomized, doubleblind, placebo-controlled trial comparing pamidronate 60 mg iv every 3 months with placebo in 40 premenopausal women with newly diagnosed breast cancer. Bone mineral density (BMD) of the spine and hip and remodeling markers were monitored over 1 yr. Results: Over half of the subjects became amenorrheic, and those who did were 4 yr older than those who did not (P = 0.02). The mean difference in percent change in BMD at 12 months between the two treatment groups was 5.1percent at the lumbar spine (P = 0.002) in the overall study group and 5percent at the lumbar spine and 5.2percent at the total hip in the amenorrheic subgroup (P 0.03). Biochemical markers of bone remodeling did not differ between the two treatment groups, and treatment was well tolerated. Conclusion: Chemotherapy-induced amenorrhea is common with ensuing bone loss at the spine and hip. Pamidronate prevented bone loss at the spine and hip and was well tolerated. Copyright © 2005 by The Endocrine Society.
dc.format.extent
dc.format.extent Pages: (3209-3214)
dc.language English
dc.publisher CHEVY CHASE
dc.relation.ispartof Publication Name: Journal of Clinical Endocrinology and Metabolism; Publication Year: 2005; Volume: 90; no. 6; Pages: (3209-3214);
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: A randomized controlled trial
dc.type Article
dc.contributor.affiliation Fuleihan, G.E.-H., Calcium Metabolism and Osteoporosis Program, Division of Endocrinology, American University of Beirut-Medical Center, Beirut 113-6044, Lebanon, Calcium Metabolism and Osteoporosis Program, American University of Beirut-Medical Center, Bliss Street, Beirut, 113-6044, Lebanon
dc.contributor.affiliation Salamoun, M., Division of Hematology and Oncology, School of Medicine, American University of Beirut-Medical Center, Beirut 113-6044, Lebanon
dc.contributor.affiliation Mourad, Y.A., Division of Hematology and Oncology, School of Medicine, American University of Beirut-Medical Center, Beirut 113-6044, Lebanon
dc.contributor.affiliation Chehal, A., Division of Hematology and Oncology, School of Medicine, American University of Beirut-Medical Center, Beirut 113-6044, Lebanon
dc.contributor.affiliation Salem, Z., Division of Hematology and Oncology, School of Medicine, American University of Beirut-Medical Center, Beirut 113-6044, Lebanon
dc.contributor.affiliation Mahfoud, Z., Department of Epidemiology and Population Health, School of Health Sciences, American University of Beirut-Medical Center, Beirut 113-6044, Lebanon
dc.contributor.affiliation Shamseddine, A., Division of Hematology and Oncology, School of Medicine, American University of Beirut-Medical Center, Beirut 113-6044, Lebanon
dc.contributor.authorAddress Fuleihan, G.E.-H.; Calcium Metabolism and Osteoporosis Program, American University of Beirut-Medical Center, Bliss Street, Beirut, 113-6044, Lebanon; email: gf01@aub.edu.lb
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine;
dc.contributor.authorDepartment Internal Medicine
dc.contributor.authorDivision
dc.contributor.authorEmail gf01@aub.edu.lb
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Fuleihan, GEH
dc.contributor.authorInitials Salamoun, M
dc.contributor.authorInitials Abou Mourad, Y
dc.contributor.authorInitials Chehal, A
dc.contributor.authorInitials Salem, Z
dc.contributor.authorInitials Mahfoud, Z
dc.contributor.authorInitials Shamseddine, A
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress Fuleihan, GEH (reprint author), Amer Univ Beirut, Med Ctr, Calcium Metab and Osteoporosis Program, Div Endocrinol, Bliss St, Beirut 1136044, Lebanon.
dc.contributor.authorResearcherID
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Berenson JR, 1996, NEW ENGL J MED, V334, P488, DOI 10.1056-NEJM199602223340802; Bjarnason NH, 2002, BONE, V30, P307, DOI 10.1016-S8756-3282(01)00662-7; CATHERINO WH, 1993, DRUG SAFETY, V8, P381; Chu KC, 1996, J NATL CANCER I, V88, P1571, DOI 10.1093-jnci-88.21.1571; Coleman RE, 2003, CANCER, V97, P880, DOI 10.1002-cncr.11124; Delmas PD, 1997, J CLIN ONCOL, V15, P955; Fogelman I, 2003, OSTEOPOROSIS INT, V14, P1001, DOI 10.1007-s00198-003-1508-y; Fuleihan GEH, 2002, BONE, V31, P520; FULEIHAN GEH, 1995, J BONE MINER RES, V10, P1004; Ganz PA, 2001, J CLIN ONCOL, V19, P3303; GENANT HK, 1994, J BONE MINER RES, V9, P1503; Headley JA, 1998, CANCER INVEST, V16, P6, DOI 10.3109-07357909809039747; Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056-NEJM199612123352401; Looker AC, 1998, OSTEOPOROSIS INT, V8, P468, DOI 10.1007-s001980050093; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056-NEJM199203263261302; Major P, 2001, J CLIN ONCOL, V19, P558; Marshall D, 1996, BRIT MED J, V312, P1254; POWLES T, 2002, J CLIN ONCOL, V20, P3224; Powles T, 2002, J CLIN ONCOL, V20, P3219, DOI 10.1200-JCO.2002.11.080; Powles TJ, 1998, J NATL CANCER I, V90, P704, DOI 10.1093-jnci-90.9.704; RALSTON SH, 1989, LANCET, V2, P1180; Reichman BS, 1994, J NATL CANC I MONOGR, V16, P125; Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056-NEJMoa011807; REYNO LM, 1993, EUR J CANCER, V29A, P21, DOI 10.1016-0959-8049(93)90569-2; Saarto T, 1997, J CLIN ONCOL, V15, P1341; Saarto T, 2001, J CLIN ONCOL, V19, P10; Shamseddine A, 2004, ANN EPIDEMIOL, V14, P663, DOI 10.1016-j.annepidem.2003.12.002; Shapiro CL, 2001, J CLIN ONCOL, V19, P3306; Smart CR, 1997, CA-CANCER J CLIN, V47, P134, DOI 10.3322-canjclin.47.3.134; Vehmanen L, 2001, EUR J CANCER, V37, P2373, DOI 10.1016-S0959-8049(01)00317-3; YOUNGER PL, 2002, ENVIRONM POLLUT SER, V5, P1
dc.description.citedCount 58
dc.description.citedTotWOSCount 47
dc.description.citedWOSCount 46
dc.format.extentCount 6
dc.identifier.articleNo
dc.identifier.coden JCEMA
dc.identifier.pubmedID 15769994
dc.identifier.scopusID 21244494910
dc.identifier.url
dc.publisher.address 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr J. Clin. Endocrinol. Metab.
dc.relation.ispartOfIssue 6
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle Journal of Clinical Endocrinology and Metabolism
dc.relation.ispartofPubTitleAbbr J. Clin. Endocrinol. Metab.
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 90
dc.source.ID WOS:000229351000011
dc.type.publication Journal
dc.subject.otherAuthKeyword
dc.subject.otherChemCAS calcium, 14092-94-5, 7440-70-2
dc.subject.otherChemCAS cyclophosphamide, 50-18-0
dc.subject.otherChemCAS doxorubicin, 23214-92-8, 25316-40-9
dc.subject.otherChemCAS epirubicin, 56390-09-1, 56420-45-2
dc.subject.otherChemCAS fluorouracil, 51-21-8
dc.subject.otherChemCAS methotrexate, 15475-56-6, 59-05-2, 7413-34-5
dc.subject.otherChemCAS pamidronic acid, 40391-99-9, 57248-88-1
dc.subject.otherChemCAS tamoxifen, 10540-29-1
dc.subject.otherChemCAS calcifediol, 19356-17-3
dc.subject.otherChemCAS Antineoplastic Agents
dc.subject.otherChemCAS Calcifediol, 19356-17-3
dc.subject.otherChemCAS Diphosphonates
dc.subject.otherChemCAS pamidronate, 40391-99-9
dc.subject.otherChemCAS Placebos
dc.subject.otherChemCAS Tamoxifen, 10540-29-1
dc.subject.otherIndex anthracycline
dc.subject.otherIndex biochemical marker
dc.subject.otherIndex calcium
dc.subject.otherIndex cyclophosphamide
dc.subject.otherIndex doxorubicin
dc.subject.otherIndex epirubicin
dc.subject.otherIndex fluorouracil
dc.subject.otherIndex methotrexate
dc.subject.otherIndex pamidronic acid
dc.subject.otherIndex placebo
dc.subject.otherIndex tamoxifen
dc.subject.otherIndex vitamin D
dc.subject.otherIndex antineoplastic agent
dc.subject.otherIndex bisphosphonic acid derivative
dc.subject.otherIndex calcifediol
dc.subject.otherIndex pamidronic acid
dc.subject.otherIndex tamoxifen
dc.subject.otherIndex adult
dc.subject.otherIndex amenorrhea
dc.subject.otherIndex article
dc.subject.otherIndex bone mineral
dc.subject.otherIndex bone remodeling
dc.subject.otherIndex breast cancer
dc.subject.otherIndex cancer diagnosis
dc.subject.otherIndex cancer patient
dc.subject.otherIndex clinical article
dc.subject.otherIndex clinical trial
dc.subject.otherIndex controlled clinical trial
dc.subject.otherIndex controlled study
dc.subject.otherIndex double blind procedure
dc.subject.otherIndex drug efficacy
dc.subject.otherIndex drug tolerability
dc.subject.otherIndex female
dc.subject.otherIndex flu like syndrome
dc.subject.otherIndex hip
dc.subject.otherIndex human
dc.subject.otherIndex hypocalcemia
dc.subject.otherIndex lumbar spine
dc.subject.otherIndex monitoring
dc.subject.otherIndex osteolysis
dc.subject.otherIndex premenopause
dc.subject.otherIndex priority journal
dc.subject.otherIndex randomized controlled trial
dc.subject.otherIndex side effect
dc.subject.otherIndex spine
dc.subject.otherIndex blood
dc.subject.otherIndex breast tumor
dc.subject.otherIndex cancer staging
dc.subject.otherIndex chemically induced disorder
dc.subject.otherIndex comparative study
dc.subject.otherIndex pathophysiology
dc.subject.otherIndex postmenopause osteoporosis
dc.subject.otherIndex premenopause
dc.subject.otherIndex Adult
dc.subject.otherIndex Antineoplastic Agents
dc.subject.otherIndex Antineoplastic Combined Chemotherapy Protocols
dc.subject.otherIndex Breast Neoplasms
dc.subject.otherIndex Calcifediol
dc.subject.otherIndex Diphosphonates
dc.subject.otherIndex Double-Blind Method
dc.subject.otherIndex Female
dc.subject.otherIndex Humans
dc.subject.otherIndex Neoplasm Staging
dc.subject.otherIndex Osteoporosis, Postmenopausal
dc.subject.otherIndex Placebos
dc.subject.otherIndex Premenopause
dc.subject.otherIndex Tamoxifen
dc.subject.otherKeywordPlus MINERAL DENSITY
dc.subject.otherKeywordPlus ADJUVANT CHEMOTHERAPY
dc.subject.otherKeywordPlus POSTMENOPAUSAL WOMEN
dc.subject.otherKeywordPlus ZOLEDRONIC ACID
dc.subject.otherKeywordPlus OVARIAN FAILURE
dc.subject.otherKeywordPlus CLODRONATE
dc.subject.otherKeywordPlus CYCLOPHOSPHAMIDE
dc.subject.otherKeywordPlus ABSORPTIOMETRY
dc.subject.otherKeywordPlus HYPERCALCEMIA
dc.subject.otherKeywordPlus METHOTREXATE
dc.subject.otherWOS Endocrinology and Metabolism


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


Browse

My Account